about
The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseCYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with CyclophosphamideCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisGenetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeGenetic variations in multiple myeloma II: association with effect of treatment.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Breath tests to phenotype drug disposition in oncology.The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma.Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
P2860
Q26830005-359F9A4B-FC1F-4650-9AB2-7DFEE56F3229Q28068930-5B073C5F-A77E-40E1-8EFE-CC1FF83CE7F2Q28552450-40C1D4CD-1954-4DDD-9C47-22DFB9B26700Q30418239-ECDD50A9-E28F-4EEC-890A-BCACDF2FC89AQ33747406-4D5EB1FF-18F5-428B-8B61-A7DC7C8F368FQ36336024-9A3F4C9E-CE5E-4E9E-B45E-0698D1EF466BQ36802054-EE9F0B90-529F-46FF-A4FF-1BBB7900567AQ36944006-3A25C143-9B83-4F8A-8925-AE1E6BCE57B1Q37924890-C748B0A9-AF25-4FE9-B655-C747884C5655Q37939200-44F4B117-9B09-4A67-8A57-F1202635C71CQ38122635-7F053702-E858-4195-9503-39076789E32DQ38373316-E504FF2A-7F58-4D5B-99B0-D5957EF747FBQ40785035-3B52E4A8-EDD1-459B-9022-8B20BF35822AQ43110263-D14F54A9-DBC8-494F-A86D-AC235D9BD2A4Q43150200-FF8A467F-FCF8-4CE8-93FC-CD05347D7716Q44028238-B1E1E17B-13A5-4A60-A7E1-61207E1BD411Q46250643-8FEE4D31-93E9-4D4C-9971-C9F4AC05C89EQ49618000-86D99391-68F6-45C6-B426-9B33ADF0E6ABQ50271114-DCD98E99-DA2D-4412-93A1-C125E7B6B21CQ51144588-340EB333-CF20-40AC-B5F7-862FD5F132C2Q51399624-EE167BB6-F2AC-48EA-901E-4BAAD27E3B5AQ51573777-4A664A1D-31E0-4CCF-B9F1-B9AE95F8C0ADQ54686050-57875081-76D5-43CE-A5DF-2EC5DA155351
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Antimycotic drug discovery in the age of genomics.
@ast
Antimycotic drug discovery in the age of genomics.
@en
type
label
Antimycotic drug discovery in the age of genomics.
@ast
Antimycotic drug discovery in the age of genomics.
@en
prefLabel
Antimycotic drug discovery in the age of genomics.
@ast
Antimycotic drug discovery in the age of genomics.
@en
P2093
P2860
P356
P1476
Antimycotic drug discovery in the age of genomics.
@en
P2093
John D Cleary
Larry A Walker
Roy L Hawke
P2860
P2888
P304
P356
10.1038/SJ.TPJ.6500330
P577
2005-01-01T00:00:00Z